E-Motion’s New Stimulation Therapy for Patients With Acute Digestive Dysmotility Gets CE Mark Approval

E motion GID

E-Motion Medical Ltd, a Tel Aviv, Israel-based Medtech company, received CE Mark approval for its groundbreaking E-Motion System™, which provides stimulation therapy to restore esophageal and GI motor function for patients with impaired motility, common in critically ill, neurological, surgical, geriatric, neonatal or severe diabetic patients.

Read more Wearable Stomach Monitor Tracks Electrical Activity for Signs of Indigestion

Gastrointestinal dysmotility (GID) is abnormal intestinal contractions, such as spasms and intestinal paralysis. GID is a variety of disorders in which the gut has lost its ability to coordinate muscular activity because of endogenous or exogenous causes. Millions of patients all over the globe suffer from gastrointestinal dysmotility. In addition, gut motility has been shown to have correlation to other physical function in the body, including that of the diaphragm and the lungs, and other systems required for patient recovery. To date, there is no adequate treatment for GID.

Founded in 2011, E-Motion Medical developed the first non-pharmaceutical therapy for restoring the natural motor function of the digestive system for people suffering from digestive dysmotility, said a press release.

To restore motility to the digestive system, the E-Motion System delivers unique patterns of electrical stimulation to the esophagus using the Company’s proprietary applicator, the E-Motion Tube, which is easily placed by the nursing staff in the same manner as a regular feeding tube. The applied stimulation generates contractions, which restore natural function to the digestive system and promote motility throughout the gastrointestinal tract.

E motion GID
Layers of the Gastrointestinal tract (Image: Creative commons)

So far, the company tested the E-Motion System on approximately 230 people in four clinical trials, conducted in 12 hospitals in Europe and Canada.

The latest trial involving 155 patients, was a randomized, sham-controlled, double-blinded trial. This study was recently completed, demonstrating that the treatment provided by the E-Motion System promotes gastric motility, reduces risk of aspirations, and speeds up recovery.

Read more DFree Wearable Device for Urinary Incontinence Launches in US

“There is currently no adequate solution for the widespread problem of acute digestive dysmotility. Our technology provides a new and first of its kind therapy to promote the physical function of the digestive system, and consequently improve outcomes and lower financial burden on the healthcare system,” said Amichay H. Gross, Co-Founder and CEO of E-Motion Medical. “The CE Mark is an important milestone for E-Motion Medical, as it will allow commercial access to hospitals across Europe.”

Previous articleResearchers Develop Wearable Paper-Based UV Sensors that Warn You When it’s Time to Get Out of the Sun
Next articleBMCC Professor Finds Problematic Assumptions About Gender Within the Field of Tech Development
Cathy Russey () is Online Editor at WT | Wearable Technologies and specialized in writing about the latest medical wearables and enabling technologies on the market. Cathy can be contacted at info(at)wearable-technologies.com.